BR0016463A - N- (1-phenylethyl) -5-phenyl-imidazole-2-amine compounds, their compositions and uses - Google Patents

N- (1-phenylethyl) -5-phenyl-imidazole-2-amine compounds, their compositions and uses

Info

Publication number
BR0016463A
BR0016463A BR0016463-1A BR0016463A BR0016463A BR 0016463 A BR0016463 A BR 0016463A BR 0016463 A BR0016463 A BR 0016463A BR 0016463 A BR0016463 A BR 0016463A
Authority
BR
Brazil
Prior art keywords
phenyl
compounds
compositions
amine compounds
phenylethyl
Prior art date
Application number
BR0016463-1A
Other languages
Portuguese (pt)
Inventor
Song Liu
Benjamin Eric Blass
David Edward Portlock
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of BR0016463A publication Critical patent/BR0016463A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/68—Halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Abstract

"COMPOSTOS DE N-(1-FENILETIL)-5-FENIL-IMIDAZOL-2-AMINA, SUAS COMPOSIçõES E USOS". A invenção exposta refere-se aos compostos tendo a estrutura em que cada R1 é independentemente alquila, arila, ou heterociclo; cada R2, R4, R7, e R8 é independentemente hidrogênio ou outro substituinte; A é arila ou heterociclo; e as suas formas farmaceuticamente aceitáveis. A invenção exposta também refere-se as composições farmacêuticas contendo tais compostos, e os métodos para tratar ou prevenir doenças ou distúrbios usando tais compostos."N- (1-PHENYLETYL) -5-PHENYL-IMIDAZOL-2-AMINE COMPOUNDS, THEIR COMPOSITIONS AND USES". The exposed invention relates to compounds having the structure in which each R1 is independently alkyl, aryl, or heterocycle; each R2, R4, R7, and R8 is independently hydrogen or another substituent; A is aryl or heterocycle; and their pharmaceutically acceptable forms. The exposed invention also relates to pharmaceutical compositions containing such compounds, and methods for treating or preventing diseases or disorders using such compounds.

BR0016463-1A 1999-12-17 2000-12-14 N- (1-phenylethyl) -5-phenyl-imidazole-2-amine compounds, their compositions and uses BR0016463A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17270999P 1999-12-17 1999-12-17
US19281100P 2000-03-29 2000-03-29
PCT/US2000/033820 WO2001044203A1 (en) 1999-12-17 2000-12-14 N-(1-phenylethyl)-5-phenyl-imidazole-2-amine compounds, their compositions and uses

Publications (1)

Publication Number Publication Date
BR0016463A true BR0016463A (en) 2002-08-27

Family

ID=26868376

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0016463-1A BR0016463A (en) 1999-12-17 2000-12-14 N- (1-phenylethyl) -5-phenyl-imidazole-2-amine compounds, their compositions and uses

Country Status (16)

Country Link
EP (1) EP1237876A1 (en)
JP (1) JP2003516972A (en)
KR (1) KR20020062339A (en)
CN (1) CN1411449A (en)
AU (1) AU2096901A (en)
BR (1) BR0016463A (en)
CA (1) CA2394570A1 (en)
CO (1) CO5261516A1 (en)
CZ (1) CZ20021834A3 (en)
HU (1) HUP0204144A3 (en)
IL (1) IL149749A0 (en)
MX (1) MXPA02005957A (en)
NO (1) NO20022844L (en)
PE (1) PE20010928A1 (en)
PL (1) PL356172A1 (en)
WO (1) WO2001044203A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY146532A (en) 2004-03-05 2012-08-15 Taisho Pharmaceutical Co Ltd Thiazole derivative
EP2513064B1 (en) 2009-12-17 2018-07-04 Katholieke Universiteit Leuven, K.U. Leuven R&D Compounds, compositions and methods for controlling biofilms

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459763A (en) * 1966-01-25 1969-08-05 Geigy Chem Corp Certain amino imidazole derivatives
JPS54112864A (en) * 1978-02-22 1979-09-04 Teijin Ltd Novel imidazole derivative, its mineral acid salt, and their preparation
DD135724A1 (en) * 1978-04-14 1979-05-23 Annemarie Hetzheim PROCESS FOR THE PREPARATION OF 2-AMINO-3-PHENACYL-BENZOXAZOLIUM HALOGENIDES AND 2-AMINO-1-O-HYDROXYPHENYL-4-ARYL-IMIDAZOLENE
US4348404A (en) * 1980-07-21 1982-09-07 E. I. Du Pont De Nemours And Company Antiinflammatory 4,5-diaryl-α-polyfluoroalkyl-1H-imidazole-2-methanamines
JPH0753716B2 (en) * 1986-07-02 1995-06-07 吉富製薬株式会社 Imidazol carboxamide derivative
CN1350539A (en) * 1999-05-19 2002-05-22 宝洁公司 Imidazo-containing heterocyclic compounds, their compositions and uses

Also Published As

Publication number Publication date
CN1411449A (en) 2003-04-16
CA2394570A1 (en) 2001-06-21
PL356172A1 (en) 2004-06-14
AU2096901A (en) 2001-06-25
CO5261516A1 (en) 2003-03-31
MXPA02005957A (en) 2002-10-23
IL149749A0 (en) 2002-11-10
KR20020062339A (en) 2002-07-25
CZ20021834A3 (en) 2002-10-16
PE20010928A1 (en) 2001-09-12
HUP0204144A3 (en) 2003-07-28
JP2003516972A (en) 2003-05-20
WO2001044203A1 (en) 2001-06-21
NO20022844L (en) 2002-08-19
NO20022844D0 (en) 2002-06-14
EP1237876A1 (en) 2002-09-11
HUP0204144A2 (en) 2003-05-28

Similar Documents

Publication Publication Date Title
TR200201505T2 (en) Pirazolopyrimidines as therapeutic agents
BR0111913A (en) Gabapentin analogs for sleep disorders
ES2193391T3 (en) MUSCARINIC ANTAGONISTS.
PA8481301A1 (en) DERIVATIVES OF 4,4-BIARILPIPERIDINA
BR9806413A (en) Compound and use thereof
BG66085B1 (en) Phenylalanine derivatives
ES2175161T3 (en) PIPERAZINE DERIVATIVES AS TAQUIQUININE ANTAGONISTS.
BR9807876A (en) Heterocyclic compounds and their use for inhibition of beta-amyloid peptide
TR200001279T2 (en) Poly (ADP-ribose) polymerase ("PARP") inhibitors, methods and pharmaceutical compositions for the treatment of neural and cardiovascular tissue damage.
ATE206611T1 (en) USE OF MANGIFERIN OR ITS DERIVATIVES FOR COSMETIC USE
AR028810A1 (en) DERIVATIVES OF ARILPIPERAZINIL-CICLOHEXIL INDOL, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM AND THE USE OF THE SAME FOR THE MANUFACTURE OF MEDICINES FOR THE TREATMENT OF DEPRESSION
BR0312232A (en) Caspase inhibitors and their uses
NO990433L (en) New compounds and compositions for the treatment of diseases associated with tryptase activity
DE60045508D1 (en) DALDA ANALOGS AND THEIR USE
ATE425142T1 (en) INHIBITORS OF C-JUN N-TERMINAL KINASES (JNK)
BR0215151A (en) Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands
DK599789D0 (en) 3,5-DI-TERTIAER-BUTYL-4-HYDROXYPHENYL-1,3,4-THIADAZOLES AND OXADIAZOLES, AND 3,5-DI-TERTIAER-BUTYL-4-HYDROXYPHENYL-1,2,4-THIADAZOLES, OXADIAZOLES AND -TRIAZOLES AS ANTI-INFLAMMATORY AGENTS
FI965021A0 (en) Benzimidazole derivatives with dopaminergic effect on central nervous system
BR0315662A (en) 1- (4-Benzyl-piperazin-1-yl) -3-phenyl-propenone derivatives
PA8487701A1 (en) DERIVATIVES OF 3,3-BIARYLIPIPERIDINE AND 2,2-BIARYLMORPHOLINE
AR020563A1 (en) TIA-ALQUINOIC COMPOUNDS (POLI) AND THEIR DERIVATIVES, COMPOSITIONS THAT INCLUDE THEM AND THEIR USE
UY26426A1 (en) NEW COMPOUNDS
DK0527081T3 (en) Newly substituted 3-piperazinylalkyl-2,3-dihydro-1,3-4H-benzoxazin-4-ones, their preparation and therapeutic use
TR200000153T2 (en) 6-azauracil derivatives that inhibit il-5.
ATE266029T1 (en) SUBSTITUTED PYRROLOBENZIMIDAZOLE DERIVATIVES FOR ANTI-INFLAMMATORY

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]